Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021

Once oncology drugs are converted from accelerated to full approval, new evidence of OS or QoL gains remains rare, underscoring the need to ensure such evidence is available at conversion. Patients should be informed of evidence variability, and the ESMO-MCBS can provide valuable guidance.